Dostie will be in charge of Nano­biotix’ operations, including development, manufacturing, market access, and sales, particularly for the lead product NBTXR3. The radio-enhancer could reach a CE market approval and a first phase II/III interim readout this year. Dostie, who holds a Bachelor of Science in Human Biology, joins the company after 25 years of international experience in the  pharmaceutical industry, especially in market access and oncology. Previously, he worked as Oncology General Manager at Novartis Pharma GmbH in Germany.